2 times and less than 3 times the upper limit of normal) of liver associated enzymes was 6% for
CELEBREX and 5% for placebo, and approximately 0.2% of
patients taking CELEBREX and 0.3% of patients taking placebo had notable elevations of ALT and AST.
A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be monitored carefully for evidence of the development of a more severe hepatic reaction while on therapy with CELEBREX.